The Italian Agency for Drugs admitted the refundability of the gene therapy with Zolgensma at expense of the National Healthcare System for every child who suffers from SMA, with a weight under 13,5 kilos. The active substance of this therapy, the Onasemnogene Abeparvovec, consists of human gene material capable of treating a severe degenerative disease...Read More